

This document is to help guide the use of the provided WRHN IV Iron package. The documents included in the IV Iron Sucrose Package are:

1. Adult Outpatient Iron Sucrose Order set (page 2 and 3)

Use this document to help determine:

- (1) If the patient is a candidate for IV Iron therapy
- (2) If the IV Iron therapy will be paid for by WRHN or by the patient

AND

to order IV Iron to be administered at WRHN @ Midtown. (Note: if the patient is to pay for the IV Iron they will also require a separate outpatient prescription)

2. Form 1: Facilitating Patient Payment for IV Iron (page 4)

This document provides guidance for payment options for patients that have to pay for their own Iron Sucrose.

3. Form 2: IV Iron Sucrose EAP request form (page 5)

This document can be used for patients who are ODB eligible to request Exceptional Access Program Coverage.

We suggest keeping these documents for your records to help you with ordering IV Iron for patient's in the future, however if you need a new package or any of the forms listed above please contact Medical Day Unit at WRHN @ Midtown at 519-749-4300 ext 2126.



ROUTINE ORDERS

Adult Outpatient Intravenous Iron Order Set

Prescriber instructions: 1) The property 2) An order with a black box ■ will						
			Allergies, 🗆 Ner			<i>'</i> ^
Date:	Time:	Weight (kg):	Review electron		*Order #	Initials
year/month/day		Height (cm):	_		ō '	Init
	 notiont Admir			Must be semplete and		
Required Criteria for Outpattach laboratory reports				- wust be complete and		
All of the following criteria n			161			
☐ 1. Diagnosis of iron deficien	icv anemia: Her	noalohin (Hah) level le	ss than 120a/L in female	es or less than 130g/L in		
males AND	ioy arioirila. Fior	noglobin (rigb) lover lov	oo man 120g/2 iii lomale	75 61 1666 triair 1669/2 iii		
☐ 2. Low iron stores as demor	nstrated by: trar	sferrin saturation (TSA	T) less than 20% (0.20)	AND/OR ferritin less than		
15 mcg/L AND		,	, , ,			
☐ 3. Insufficient time (4 weeks						
OR documented intolerance/in				oility to absorb oral iron		
Eligibility for insured serv						
☐ WRHN Pays – intravenous						
Ferric Derisomaltose is patie						
INSURED HOSPITAL SERVICE	CE, such as a sı	urgical procedure, diag	nostic test or treatment)	Provide details and		
date:	-4 b-! !-4					
☐ Patient Pays - patient mu intravenous iron administration						
Refer patient to WRHN @ Mid						
☐ Patient has been provided v				gate patient funding options.		
☐ EAP application submitted of		(date)	003 11011			
Lab work and Diagnostics		()				
☐ CBC, Ferritin at final sch		tment				
☐ Iron Studies at final sche						
IV fluid	даной арронн	THO IT			<u>_</u>	
■ Peripheral saline lock, if i	needed					
■ Sodium Chloride 0.9% 25		L/hr				
Medication					!	
Premedication (consider if	patient has h	ad reaction during pr	evious iron infusion)			
■ DiphenhydrAMINE 50mg		■ prn for reaction [
☐ Hydrocortisone 100mg I		□ prn for reaction I				
☐ DimenhyDRINATE 50mg			□ pre infusion			
☐ Acetaminophen 1000mg			□ pre infusion			
_ / to a tall		_ p	_ p. c			
Intravenous Iron - See re	verse for dos	ing. If more than a	course of therapy is	needed (based on		
maximum dose), after cor						
new blood work meeting			,			
☐ Specify type of intraveno			conate compley).			
				m 6 doses/course) OR		
☐ Ferric Derisomaltose (s						
(Maximum 1 course per						
required) give						
. , , ,	IIIg IV X I C	iose at least / days	alter the mist dose (ma	aximum rooonig		
per single dose)						
Monitoring			· f · · · · · · · · · · · · · · · · · ·			
■ Monitor for signs and syn	nptoms of hyp	ersensitivity reaction	s for at least 30 minut	es post infusion and		
until clinically stable.	/Clariaal\					
*Enter Order # and initial (by Nurse	e/Cierical)					
Prescriber Sig	nature:					
Transcriber Si	gnature:		Date:	Time:		

Nurse Reviewer Signature: ______Date: _____Time: _____

Calculating Iron Replacement Requirements	
Normal Hgb; Women: Greater than 120g/L Men: Greater	er than 130g/L
Hgb deficit (g/L) = target Hgb – actual Hgb	Deficit =
Total iron dose required (mg) = (Hgb deficit x 20) + 500	Total Iron requirements= Divide total iron requirement by intravenous iron dose to determine number of infusions.

Intravenous Iron Pr	rescribing Guidelin	es (See GRH IV manual	or Product Monograph for	more information)
IV Iron Sucrose (Venofer®)	and maximum dose	ed doses with a n daily dose of 300mg e of 1000mg in 14 days of therapy per order –	Dosage regimen once per vimultiple doses within a week circumstances (preferable doses) Consider initiating at lower	ek in certain 2 to 3 days between doses for special patient
IV Iron Gluconate Complex (Ferrlecit®)	elemental iron. Ma single dose: 250mg	ed doses of 125mg aximum recommended g of therapy per order –	populations such as elderly renal patients to reduce info	
Ferric Derisomaltose	Hemoglobin (g/L)	Total Iron Dose – M	aximum dose per course o	of therapy per order
(Monoferric®)		Body weight less than 50kg	Body weight 50 to 69 kg	Body weight 70kg or greater
	100 or greater	500mg	1000mg	1500mg (given in 2 divided doses of 1000mg + 500mg 7 days apart)
	Less than 100	1000mg (given in 2 divided doses of 500mg + 500mg 7 days apart)	1500mg (given in 2 divided doses of 1000mg + 500mg 7 days apart)	2000mg (given in 2 divided doses of 1000mg + 1000mg 7 days apart)

Guidance for outpatient p	rescription			
When providing an outpatie	nt prescription	please include as follow	ws:	
Intravenous type/brand	Dose	_ mg (dose) every	(frequency) x	(number of doses)

Form 1: Facilitating Patient Payment for IV Iron

For patients obtaining their own supply of IV Iron for administration at the Medical Day Unit at WRHN @ Midtown there are 4 potential options. See below for pricing and information regarding Health Care Centre Pharmacy dispensing.

1. Private insurance

Patients contact their private insurance provider to determine if they are eligible to have IV Iron dispensed through their plan. The patient must do this on their own, but may need the drug identification number listed here

Iron Sucrose DIN: 02243716

Ferric Derisomaltose DIN: 02477777

2. Exceptional Access Coverage - Only available for IV Iron Sucrose

Physicians can apply for exceptional access for all ODB patients (including those on Trillium) for IV iron sucrose therapy. The Exceptional Access Form (Form 2) has been attached or can also be accessed from the Medical Day Unit at WRHN @ Midtown.

3. Patients pay cash

Patients can pay cash at their own community pharmacy or Health Care Centre Pharmacy at the hospital for their IV iron and pick the dose up prior to their scheduled appointment

4. Special considerations

For patients that don't have private or EAP coverage but who are unable to afford their IV iron, we will discuss these cases on an individual basis to determine the best course of action. Please contact the Clinical Manager, Medical Day Unit; 519-749-4300 ext 3956.

Health Care Centre Pharmacy Information

Cost per dose of medication for cash paying patients (prices are subject to change)

Iron Sucrose (Venofer)	Approximate
Dose	Cost
100mg	\$53
200mg	\$96
300mg	\$140
400mg	\$183
500mg	\$227

Ferric Derisomaltose (Monoferric)	Approximate Cost
500mg	\$274
1000mg	\$535

- Monoferric requires fewer visits to infuse the same amount of iron.
- Most private drug plans currently cover Monoferric without any prior authorization requirement

Reasons to use HCCP for IV Iron

- Convenience pick up your Iron on the way to your appointment
- Supply HCCP will always have supply of IV Iron available for our Medical Day Unit Patients
- Quick and friendly service HCCP will only need 30 minute notice to fill your IV Iron prescription

FORM 2: IV iron sucrose EAP request form

To be completed and submitted for Ontario Drug Benefit (ODB) patients (e.g. over 65 years, on social assistance, or covered through Trillium Drug Program)

Exceptional Access Program (EAP) Request for Iron Sucrose (Venofer) for the Treatment of Iron-Deficiency Anemia

Fax the completed form and/or any additional relevant information to (416) 327-7526 or toll free to 1-866-811-9908; OR send to EAPB Ontario Public Drug Programs, Exceptional Access Program Branch, 3rd Floor, 5700 Yonge Street, Toronto, ON, M2M 4K5

Section 1 - Prescriber Information First name Initial Last name Initial Last name First name Initial Last name Initial Last name Initia
Street no. Street name Postal code Fax no. Telephone no. Date of birth (yyyy/mm/dd)
Street no. Street name Postal code Fax no. Telephone no. Date of birth (yyyy/mm/dd)
Postal code
Telephone no.
Telephone no.
New request
New request
Section 3 – Drug, Dose and Regimen Requested Drug product: Iron sucrose (Venofer) 100mg/5mL vial(s) Dose: Frequency: Number of doses: Section 4 – Laboratory Results (Attach a copy of the results or submit the following results indicated below) Diagnosis of iron-deficiency anemia has been confirmed with documented bloodwork Hemoglobin:g/L MCV:fL Date collected: If Hemoglobin less than 120 g/L in females or less than 130 g/L in males or MCV less than 75fL or greater than 120fL, provide to following: Date Drawn
Drug product: Iron sucrose (Venofer) 100mg/5mL vial(s) Dose: Frequency: Number of doses: Section 4 – Laboratory Results (Attach a copy of the results or submit the following results indicated below) Diagnosis of iron-deficiency anemia has been confirmed with documented bloodwork Hemoglobin: g/L MCV: fL Date collected: If Hemoglobin less than 120 g/L in females or less than 130 g/L in males or MCV less than 75fL or greater than 120fL, provide t following: Date Drawn Level Date Drawn Level Ferritin mcg/L Serum Iron Levels mcg/dL TSAT Section 5 – Medication: Current and/or Previous Patient has already been treated with at least one iron product as summarized below:
Drug product: Iron sucrose (Venofer) 100mg/5mL vial(s) Dose: Frequency: Number of doses: Section 4 – Laboratory Results (Attach a copy of the results or submit the following results indicated below) Diagnosis of iron-deficiency anemia has been confirmed with documented bloodwork Hemoglobin: g/L MCV: fL Date collected: If Hemoglobin less than 120 g/L in females or less than 130 g/L in males or MCV less than 75fL or greater than 120fL, provide to following: Date Drawn Level Date Drawn Level Ferritin mcg/L Serum Iron Levels mcg/dL TSAT % Total iron binding capacity (TIBC) Section 5 – Medication: Current and/or Previous Patient has already been treated with at least one iron product as summarized below:
Dose:
Frequency:
Section 4 - Laboratory Results (Attach a copy of the results or submit the following results indicated below) Diagnosis of iron-deficiency anemia has been confirmed with documented bloodwork Hemoglobin:g/L
Section 4 – Laboratory Results (Attach a copy of the results or submit the following results indicated below) Diagnosis of iron-deficiency anemia has been confirmed with documented bloodwork Hemoglobin:g/L
□ Diagnosis of iron-deficiency anemia has been confirmed with documented bloodwork Hemoglobin:g/L MCV:fL Date collected: If Hemoglobin less than 120 g/L in females or less than 130 g/L in males or MCV less than 75fL or greater than 120fL, provide to following: Date Drawn
□ Diagnosis of iron-deficiency anemia has been confirmed with documented bloodwork Hemoglobin:g/L MCV:fL Date collected: If Hemoglobin less than 120 g/L in females or less than 130 g/L in males or MCV less than 75fL or greater than 120fL, provide to following: Date Drawn
Hemoglobin:g/L MCV: fL Date collected: If Hemoglobin less than 120 g/L in females or less than 130 g/L in males or MCV less than 75fL or greater than 120fL, provide to following: Date Drawn
If Hemoglobin less than 120 g/L in females or less than 130 g/L in males or MCV less than 75fL or greater than 120fL, provide to following: Date Drawn
following: Date Drawn
Date Drawn Level Date Drawn Level Ferritin mcg/L Serum Iron Levels mcg/dL TSAT % Total iron binding capacity (TIBC) mcg/dL Section 5 − Medication: Current and/or Previous □ Patient has already been treated with at least one iron product as summarized below:
Ferritin mcg/L Serum Iron Levels mcg/dL TSAT % Total iron binding mcg/dL capacity (TIBC) Section 5 – Medication: Current and/or Previous Patient has already been treated with at least one iron product as summarized below:
TSAT % Total iron binding capacity (TIBC) Section 5 – Medication: Current and/or Previous Patient has already been treated with at least one iron product as summarized below:
Section 5 – Medication: Current and/or Previous □ Patient has already been treated with at least one iron product as summarized below:
Section 5 – Medication: Current and/or Previous □ Patient has already been treated with at least one iron product as summarized below:
□ Patient has already been treated with at least one iron product as summarized below:
Medication and Name Dose Start Date Duration
Oral Iron
Oral Iron
IV Iron
AND
□ Patient has demonstrated intolerance to oral iron therapy
OR .
□ Patient has not responded to an adequate therapy with oral iron
The information on this form is collected under the authority of the <i>Personal Health Information Protection Act</i> , 2001, S. O. 2001, c.3, Sched. A (PHIPA) and Sect the <i>Ontario Drug Benefit Act</i> , R. S. O. 1990c.O.10 and will be used in accordance with PHIPA, as set out in the Ministry of Health and Long-Term Care "Statemen"
Information Practices", which may be accessed at www.health.gov.on.ca If you have any questions about the collection or use of this information, call the Ontario
Benefit (ODB) Help Desk at 1800-668-6641 or contact the Director, Exceptional Access program Branch (EAPB), Ministry of Health and Long-Term Care, 3rd floor,
Yonge St., Toronto, Ontario M2M 4K5 \
Tonge set, totalies, situation many to
Prescriber signature (mandatory) CPSO number Date